Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

SXTP | 60 Degrees Pharmaceuticals Inc

Index	-	P/E	-	EPS (ttm)	-	Insider Own	13.44%	Shs Outstand	5.78M	Perf Week	-11.81%
Market Cap	1.81M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.06M	Perf Month	-48.02%
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float / Ratio	1.33% / 0.03	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.03M	Perf Half Y	-
Book/sh	-3.85	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	0.01	P/C	90.31	EPS next 5Y	-	ROE	-	52W Range	0.67 - 8.65	Perf YTD	-83.78%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-91.23%	Beta	-
Dividend %	-	Quick Ratio	0.17	Sales past 5Y	28.62%	Gross Margin	-	52W Low	13.27%	ATR	0.16
Employees	2	Current Ratio	0.19	Sales Q/Q	-	Oper. Margin	-	RSI (14)	25.50	Volatility	10.63% 9.62%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.06	Prev Close	0.67
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.06M	Price	0.76
Recom	-	SMA20	-34.04%	SMA50	-54.05%	SMA200	-57.93%	Volume	64,615	Change	13.27%

Sep-18-23 04:16PM	60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements (GlobeNewswire)
Sep-06-23 07:31AM	60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 09:00AM	Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Aug-30-23 07:32AM	60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity (GlobeNewswire) +7.04%
Aug-22-23 07:31AM	60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria (GlobeNewswire) -5.92%
07:31AM	Loading…
Aug-15-23 07:31AM	60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov (GlobeNewswire) +7.23%
Jul-31-23 07:59AM	60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects (GlobeNewswire) +6.16%
Jul-21-23 09:00AM	60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE) -8.56%
Jul-14-23 01:30PM	WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit (PR Newswire) -15.67%
12:39PM	60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering (GlobeNewswire)
Jul-12-23 01:45PM	WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit (PR Newswire)
12:29PM	60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SXTP | 60 Degrees Pharmaceuticals Inc

Upgrade your FINVIZ experience